Compare · ECOR vs MDT
ECOR vs MDT
Side-by-side comparison of electroCore Inc. (ECOR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.50B, about 2183.3x ECOR ($48.8M).
- Over the past year, ECOR is down 13.8% and MDT is down 7.3% - MDT leads by 6.6 points.
- MDT has been more active in the news (2 items in the past 4 weeks vs 1 for ECOR).
- MDT has more recent analyst coverage (25 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- Medtronic plc.
- Price
- $6.13+5.87%
- $83.19-0.41%
- Market cap
- $48.8M
- $106.50B
- 1M return
- -29.34%
- +2.28%
- 1Y return
- -13.84%
- -7.27%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 2
- Recent ratings
- 2
- 25
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ECOR
- New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
- electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
- Former Officer & Director Goldberger Daniel S sold $544,000 worth of shares (80,000 units at $6.80), decreasing direct ownership by 27% to 211,471 units (SEC Form 4)
- Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
- electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
- CFO and Interim President Lev Joshua S. sold $60,003 worth of shares (6,667 units at $9.00), decreasing direct ownership by 7% to 84,889 units (SEC Form 4)
- SEC Form 144 filed by electroCore Inc.
- Director Errico Thomas J. bought $59,852 worth of shares (9,992 units at $5.99), increasing direct ownership by 3% to 360,071 units (SEC Form 4)
- CFO and Interim President Lev Joshua S. sold $19,500 worth of shares (3,000 units at $6.50), decreasing direct ownership by 3% to 91,556 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by electroCore Inc.
Latest MDT
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)